Skip to main content
SpringerLink
Log in

Haploidentical Stem Cell Transplantation

  • Chapter
Allogeneic Stem Cell Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Allogeneic stem cell transplantation has been performed clinically for more than 30 yr as therapy for a number of different hematologic malignancies, genetic disorders, and immunologic deficiency syndromes (1,2). In most instances, the donor stem cells were obtained from sibling-matched donors. Patient outcome after transplant has been influenced by many factors, such as patient age, disease type, duration and stage at transplant, and cytomegalovirus (CMV) serologic status of the patient and donor. The best results with allogeneic transplant have been obtained in patients who have disease responsive to chemotherapy and who received hematopoietic stem cells obtained from human leukocyte antigen (HLA)-matched sibling donors. Even in this setting, this proceedure has been associated with substantial morbidity and mortality, predominantly due to the occurrence of acute and chronic graft-vs-host disease (GVHD), opportunistic infection, visceral organ dysfunction, or a combination of these. Until recently, the vast majority of patients received bone marrow as the source of hematopoietic stem cell graft. Recent data support the use of donor hematopoietic stem cells obtained from peripheral blood rather than bone marrow, especially in more advanced disease states (3). Despite the drawbacks noted above, allogeneic stem cell transplantation remains a treatment modality that has provided curative therapy for many patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827–838.

    Article  PubMed  CAS  Google Scholar 

  2. Thomas ED. Bone marrow transplantation:a review. Semin Hematol 1999; 36 (Suppl 7): 95–103.

    PubMed  CAS  Google Scholar 

  3. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  PubMed  CAS  Google Scholar 

  4. Petersdof EW, Gooley T, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515–3520.

    Google Scholar 

  5. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998; 339: 1177–1185

    Article  PubMed  CAS  Google Scholar 

  6. Lamparelli T, Van Lint MT, Gualandi F, et al. Bone marrow transplantation for chronic myeloid leukemia from unrelated and sibling donors:Single center experience. Bone Marrow Transplant 1997; 20: 1057–1062.

    Article  PubMed  CAS  Google Scholar 

  7. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLAidentical siblings. N Engl J Med 1985; 313: 765–771.

    Article  PubMed  CAS  Google Scholar 

  8. Anasetti C, Amos D, Beattyp PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.

    Article  PubMed  CAS  Google Scholar 

  9. Kernan NA, Flomenberg N, Dupont B, O’Reilly RJ. Graft rejection in recipients of T-cell-depleted HLAnonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic lymphocytes. Transplantation 1987; 43: 842–847.

    PubMed  CAS  Google Scholar 

  10. Soiffer RJ, Mauch P, Tarbell NJ, et al. Toal lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991; 7: 23–33.

    PubMed  CAS  Google Scholar 

  11. Reisner Y, Ben-Bassat I, Douer D, et al. Demonstration for clonable alloreactive host T cells in aprimate model for bone marrow transplantation. Proc Natl Acad Sci USA 1986; 83: 4012–4015.

    Article  PubMed  CAS  Google Scholar 

  12. Butturini A, Seeger RC, Gale RP. Recipient immune competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood 1986; 68: 954–956.

    PubMed  CAS  Google Scholar 

  13. Kook H, Goldman F, Padley D, et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children:immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996; 88: 1089–1097.

    PubMed  CAS  Google Scholar 

  14. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 10: 3979–3986.

    Google Scholar 

  15. Sullivan KM, Mori M, Sanders J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl 1): 127–134.

    PubMed  Google Scholar 

  16. Fleming DR, Henslee-Downey PJ, Romond EH, et al. Allogeneic bone marrow transplantation with T-celldepleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplant 1996; 17: 917–922.

    PubMed  CAS  Google Scholar 

  17. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone marrow transplantation for treatment for acute leukemia. Lancet 1983;i:612–615.

    Google Scholar 

  18. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.

    PubMed  CAS  Google Scholar 

  19. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864–3872.

    PubMed  CAS  Google Scholar 

  20. Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk acute leukemia with T cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    Article  PubMed  CAS  Google Scholar 

  21. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allograft. N Engl J Med 1999; 340: 1704–1714.

    Article  PubMed  CAS  Google Scholar 

  22. O’Reilly RJ, Collins NH, Kernan N, et al. Transplantation of marrow-depleted T cells by soybean lectin agglutination an E-rosette depletion:Major histocompatibility complex-related graft resistance in leukemic transplant recipients. Transplant Proc 1985; 17: 455, 456.

    Google Scholar 

  23. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.

    Article  PubMed  CAS  Google Scholar 

  24. Korngold R, Sprent J. T-cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335–339.

    Article  PubMed  CAS  Google Scholar 

  25. Reisner Y, KapoorN, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLAA, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61: 341–348.

    PubMed  CAS  Google Scholar 

  26. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapsed of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    PubMed  CAS  Google Scholar 

  27. Reisner Y, Martelli MF. Transplantation tolerance induced by “mega dose” CD34 cell transplants. Exp Hematol 2000; 28: 119–127.

    Article  PubMed  CAS  Google Scholar 

  28. Drobyski WR, Ash RC, Casper JT, et al. Effect of T- cell depletion as a graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980–1987.

    PubMed  CAS  Google Scholar 

  29. Guinan E. Costimulatory Blockade as a Mechanism of Inducing Tolerance in the allograft setting. Educ Book Am Soc Hematol 1999; 383–88.

    Google Scholar 

  30. Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graftversus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418–423.

    PubMed  CAS  Google Scholar 

  31. Lamb L, Gee A, Parrish R, et al. Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor:clinical and immunologic characteristics. Bone Marrow Transplant 1996; 17: 1021–1027.

    PubMed  Google Scholar 

  32. Soderling CC, Cong CW, Blazer BR, Vallera DA. A correlation between conditioning and engraftment in recipients of MHC mismatched T cell-depleted murine bone marrow transplants. Immunology 1985; 135: 941–946.

    CAS  Google Scholar 

  33. Sondel TM, Bozdech MS, Trigg ME, et al. Additional immunosuppression allows engraftment following HLAmismatched T cell-depleted bone marrow transplantation for leukemia. Transplant Proc 1985; 17: 460–462.

    Google Scholar 

  34. Champlin RE, Ho WG, Mitsuyasu R, et al. Graft failure and leukemia relapse following T lymphocyte-depleted bone marrow transplants:effect of intensification of immunosuppressive conditioning. Transplant Proc 1987; 19: 2616–2619.

    PubMed  CAS  Google Scholar 

  35. Lapidot T, Singer TS, Reisner Y. Transient engraftment of T cell depleted allogeneic bone marrow in mice improves survival rate following lethal irradiation. Bone Marrow Transplant 1988; 3: 157–164.

    PubMed  CAS  Google Scholar 

  36. Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989; 73: 2025–2032.

    PubMed  CAS  Google Scholar 

  37. Terenzi A, Lubin I, Lapidot T, et al. Enhancement of T-cell depleted bone marrow allografts in mice by thiotepa. Transplantation 1990; 50: 717–720.

    Article  PubMed  CAS  Google Scholar 

  38. Godder K, Pati AR, Abhyankar S, et al. Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT. Bone Marrow Transplant 1996; 17: 49–53.

    PubMed  CAS  Google Scholar 

  39. Kernan NA, Emanuel D, Castro-Malaspina H, et al. Posttransplant immunosuppression with antithymocyte globulin and methylprednisolone prevents immunologically mediated graft failure following a T-cell depleted marrow transplant. Blood 1989; 74: 123a.

    Google Scholar 

  40. Fischer A, Griscelli C, Blanche S, et al. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone marrow transplantation. Lancet 1986;ií:1058–1061.

    Google Scholar 

  41. Henslee-Downey PJ, Parrish RS, Macdonald JS, et al. Combined ex-vivo and in-vivo T-lymphocyte depletion for the control of graft-versus-host disease following haplo-identical marrow transplant. Transplantation 1996; 61: 738–745.

    Article  PubMed  CAS  Google Scholar 

  42. Malilay GP, Sevenich EA, Condie RM, Filipovich AH. Prevention of graft rejection in allogeneic bone marrow transplantation: I. Preclinical studies with antithymocyte globulins. Bone Marrow Transplant 1989; 4: 107–112.

    PubMed  CAS  Google Scholar 

  43. Henslee-Downey PS. Allogeneic related partially mismatched transplantation. In: Barrett J, Treleaven J (eds.), The Clinical Practice of Stem-Cell Transplantation Isis Medical Media, Oxford, 1998, pp. 391.

    Google Scholar 

  44. Henslee-Downey PJ, Godder K, Abhyankar S, Chiang KY, Lamb LS, Geier SS, Van RheeF, Singhal S, Metha J. Sequential immuno-modulation to achieve engraftment and control graft-versus-host disease across mismatched mhc barriers. Educ Book Am Soc Hematol 1999; 389–394.

    Google Scholar 

  45. Reisner Y, Martelli MF. Tolerance induction by “megadose” transplants of CD34+ stem cells:a new option for leukemia patients without an HLA-matched donor. Curr Opin Immunol 2000; 12: 536–541.

    Article  PubMed  CAS  Google Scholar 

  46. Rachmim N, Gan J, Segall R, et al. Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocytes culture. Transplatation 1998; 65: 1386–1393.

    Article  Google Scholar 

  47. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–3955.

    PubMed  CAS  Google Scholar 

  48. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16: 437–440.

    Article  PubMed  CAS  Google Scholar 

  49. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Med 1995; 1: 1268–1273.

    Article  PubMed  CAS  Google Scholar 

  50. Reisner Y, Aversa F, Bachar-Lustig E, Velardi A, Gur H, Tabilio A, Reich-Zeliger S, Krauthgamer R, Martelli MF. The role of megadose CD34 haploidentical transplantation:Potential application to tolerance induction. Educ Book Am Soc Hematol 1999; 376–382.

    Google Scholar 

  51. Cilloni D, Carlo-Stella C, Falzetti F, et al. Limited engraftment T capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 2000; 96: 3637–3643.

    PubMed  CAS  Google Scholar 

  52. Lazarus HM, Koc ON. Culture-expanded human marrow-derived MSCs in clinical hematopoietic stem cell transplantation. Graft 2001; 3: 329–333.

    Google Scholar 

  53. Lamb LS, Szafer F, Henslee-Downey, et al. Characterization of acute bone marrow graft rejection in T cell-depleted, partially mismatched related donor bone marrow transplantation. Exp Hematol 1995: 23: 1595–1600.

    PubMed  Google Scholar 

  54. Lamb LS, Gee AP, Henslee-Downey PJ, et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation frompartially mismatched related donors. Bone Marrow Transplant 1998; 21: 461–471.

    Article  PubMed  Google Scholar 

  55. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000; 96: 2299–2303.

    PubMed  CAS  Google Scholar 

  56. Volpi I, Perruccio K, Ruggeri L, et al. G-C SF blocks IL-12 production by antigen presenting cells:implications for improved immunereconsstitution afterhaploidenticalhematopoietic transplantation. Blood 1999; 10 (Suppl 1): 2841a.

    Google Scholar 

  57. Perruccio K, Tosti A, Posati S, et al. Transfer of functional immune responses to aspergillus and CMV after haploidentical hematopoietic transplantation. Blood 2000;96(11): 2383 a.

    Google Scholar 

  58. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. NEngl JMed 1995; 333: 1038–1044.

    Article  CAS  Google Scholar 

  59. Riddell SR, Greenberg PD. Adoptive immunotherapy with antigen-specific T cells. In: Thomas ED Blume KJ, Forman SJ, eds. Hematopoietic Cell Transplantation. Blackwell Science, Malden, 1999, pp. 327–341.

    Google Scholar 

  60. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.

    PubMed  CAS  Google Scholar 

  61. Weaver CH, Clift RA, Deeg HJ, et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994: 14: 885–893.

    PubMed  CAS  Google Scholar 

  62. Craig F, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265 276.

    Google Scholar 

  63. Sullivan KM, Witherspoon RP, Storb R, et al. Alternate-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72: 555–561.

    PubMed  CAS  Google Scholar 

  64. Jenkins MK, Johnson JO. Molecules involved in T-cell costimulation. Curr Opin Immunol 1993; 5: 361–367.

    Article  PubMed  CAS  Google Scholar 

  65. Steinman RM, Young JW. Signals arising from antigen-presenting cells. Curr Opin Immunol 1991; 3: 361–372.

    Article  PubMed  CAS  Google Scholar 

  66. Boussiotis VA, Gribben JG, Freeman EJ, Nadler LM. Blockade of the CD 28 co-stimulatory pathway:a means to induce tolerance. Curr Opin Immunol 1994; 6: 797–807.

    Article  PubMed  CAS  Google Scholar 

  67. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host alloantigen by antiCD40 ligand (CD40L: CD 154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 1998: 102: 473–482.

    Article  PubMed  CAS  Google Scholar 

  68. Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy:a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996; 87: 4887–4893.

    PubMed  CAS  Google Scholar 

  69. Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T-cell receptor and the a3 domain of class I MHC. Science 1991; 252: 1424–1427.

    Article  PubMed  CAS  Google Scholar 

  70. Reisner Y, Bachar-Lustig E, Li HW, et al. Purified Sca-1+Lin-stem cells can tolerize fully allogeneic host T cells remaining after sublethal TBI. Blood 1997; 90: 563a.

    Google Scholar 

  71. Bachar-Lustig E, Li HW, Marcus H, Reisner Y. Tolerance induction of megadose stem cell transplants: synergism between Sca-1+Lin cells and non-alloreactive T-cells. Transplant Proc 1998; 30: 4007, 4008.

    Google Scholar 

  72. Bachar-Lustig E, Li HW, Gur H, et al. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1 (+) Lin (-) bone marrow progenitor cells:synergism with non-alloreactive (Host x donor)F (1) T cells. Blood 1999; 94: 3212–3221.

    PubMed  CAS  Google Scholar 

  73. Lee LA, Sergio JJ, Sykes M. Natural killer cells weakly resist engrafment of allogeneic, long-term, multilineagerepopulating hematopoietic stem cells. Transplantation 1996; 61: 125–132.

    Article  PubMed  CAS  Google Scholar 

  74. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333–339.

    PubMed  CAS  Google Scholar 

  75. Ruggeri L, Capanni M, Urbani E, et al. KIR epitope incompatibility in their GvH direction predicts control of leukemia relapse after mismatched hematopoietic transplantation. Blood 2000; 96 (11): 2059a.

    Google Scholar 

  76. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000; 96: 4096–4102.

    PubMed  CAS  Google Scholar 

  77. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 year’s experience of the national marrow donor program. Blood 2000; 95: 2219 2225.

    Google Scholar 

  78. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 2000;14:502–504.

    Google Scholar 

  79. Lazarus HM, Pérez WS, Weisdorf D, Keating A, Bate-Boyle B, Klein JP, Kollman C. Autologous versus unrelated donor (URD) transplantation for acute myeloid leukemia (AML) in first or second remission (CR1 or CR2) (abstract # 1781). Blood 2000; 96: 414a.

    Google Scholar 

  80. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397–404.

    Article  PubMed  CAS  Google Scholar 

  81. Aversa F, Velardi A, Tabillo A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev 2001;15:111–119.

    Google Scholar 

  82. Aversa F, Tabilio A, Velardi A, et al. Advances in full-haplotype mismatched transplants in acute leukemia. Blood 1999;94(Suppl 1):2522a.

    Google Scholar 

  83. Bunj es D, Duncker C, Wiesneth M, et al. CD34 + selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25 (Suppl 2): 9–11.

    Article  Google Scholar 

  84. Passweg 7R, Kuhne T, Gregor M, et al. Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplant 2000; 26: 1033–1036.

    Google Scholar 

  85. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755–1759.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Hillard M. Lazarus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacob M. Rowe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Allogeneic Transplant Program, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin MD

  2. Blood and Marrow Transplant Program, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lazarus, H.M., Rowe, J.M. (2003). Haploidentical Stem Cell Transplantation. In: Laughlin, M.J., Lazarus, H.M. (eds) Allogeneic Stem Cell Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-333-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-333-0_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4481-1

  • Online ISBN: 978-1-59259-333-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation